BioSpace News Archive

Juniper Biomedical announced today that it has successfully completed an oversubscribed $2M Series Seed financing and also has been awarded $1M through the NIH Common Fund as a winner of the NIH SPARC Neuromod Prize.

Qlaris Bio, Inc. today announced the initiation and dosing of two separate U.S. Phase II masked, randomized clinical trials investigating QLS‑111 in patients with ocular hypertension and glaucoma.

Ipsen and Sutro Biopharma announced an exclusive global licensing agreement for STRO-003.

Crossject announces progress on multiple fronts in its clinical development, registration and U.S. commercial strategy and reports its financial results for the year ending December 31, 2023.

Swedish Orphan Biovitrum AB published its Annual and sustainability report for 2023. Inspired by caring and powered by science, the integrated report summarises business and strategy, financial performance, and work on sustainability.

KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted nine newly-hired employees inducement options to purchase an aggregate of 65,000 shares of KalVista common stock on April 1, 2024 as inducements material to each employee entering into employment with KalVista.

Evaxion Biotech A/S is pleased to announce the successful conclusion of a series of large non-rodent animal infection studies, testing antigens from Evaxion’s preclinical EVX-B1 vaccine candidate against Staphylococcus aureus.

Chemomab Therapeutics Ltd., a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, announced it will host a live key opinion leader virtual event on primary sclerosing cholangitis on Wednesday, April 10, 2024 at 10:00 AM ET.

Roivant and Priovant Therapeutics announced positive results from the Phase 2 study evaluating brepocitinib in non-anterior non-infectious uveitis, showing the strongest efficacy data in NIU observed to date.

Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, announced the acquisition of Modulus Therapeutics’ cell therapy platform assets, including their chimeric antigen receptor and switch receptor libraries.